Immune Checkpoint Inhibitors and Long-term Survival of Patients With Metastatic Urothelial Cancer

Alec Zhu; Jorge Alberto Garcia; Bishoy Faltas; Petros Grivas; Pedro Barata; Jonathan E Shoag

doi:10.1001/jamanetworkopen.2023.7444

Immune Checkpoint Inhibitors and Long-term Survival of Patients With Metastatic Urothelial Cancer

JAMA Netw Open. 2023 Apr 3;6(4):e237444. doi: 10.1001/jamanetworkopen.2023.7444.

Authors

Alec Zhu¹, Jorge Alberto Garcia², Bishoy Faltas³, Petros Grivas⁴, Pedro Barata², Jonathan E Shoag⁵

Affiliations

¹ Department of Urology, NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York, New York.
² Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio.
³ Division of Hematology and Medical Oncology, Department of Medicine, NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York, New York.
⁴ Fred Hutchinson Cancer Center, Division of Medical Oncology, Department of Medicine, University of Washington Medicine, Seattle.
⁵ Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio.

No abstract available

Plain language summary

This cohort study uses published clinical trial data to assess long-term survival of patients with metastatic urothelial carcinoma who are treated with immune checkpoint inhibitors.

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Carcinoma, Transitional Cell* / drug therapy
Carcinoma, Transitional Cell* / secondary
Humans
Immune Checkpoint Inhibitors* / therapeutic use
Patients

Substances

Immune Checkpoint Inhibitors
Antibodies, Monoclonal, Humanized